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Background: Calcium (Ca2+) overload occurs in failing cardiomyocytes and is partly responsible for LV dysfunction characteristic of heart 
failure (HF). High intracellular Ca2+ can activate calpains that cleave dystrophin resulting in membrane micro-tears and further rise in Ca2+. 
Poloxamer-188 (P-188), has been suggested to “repair” membrane micro-tears produced by dystrophin deficiency. This study tested the hypothesis 
that an acute i.v. bolus injection of P-188 improves LV systolic function in dogs with HF.
Methods: Studies were performed in 6 dogs with coronary microembolization-induced HF (LV ejection fraction, EF<30%). Dogs received a single 
15 mg/kg bolus injection of P-188 given over 5 minutes. Heart rate (HR), mean aortic pressure (mAoP), LV end-diastolic pressure (EDP), LV end-
diastolic (EDV) and end-systolic (ESV) volumes and EF were measured at baseline and at 1, 2, 3 and 5 hours after injection of P-188.
Result: P-188 had no effect on HR but modestly decreased mAoP. Compared to baseline, P-188 significantly decreased LV EDP, EDV and ESV and 
increased EF in a time-dependent manner. Injection of P-188 did not evoke de-novo atrial or ventricular arrhythmias.
Conclusions: In dogs with HF, acute intravenous injection of P-188 decreased LV size and improved LV systolic function without eliciting positive 
chronotropic effects or provoking de-novo ventricular arrhythmias. Further exploration of P-188 as a potential therapeutic for the treatment of HF is 
warranted. 
Baseline 1 Hour 2 Hours 3 Hours 5 Hours
HR (beats/min) 78 ± 5 78 ± 4 78 ± 5 79 ± 6 80 ± 5
mAoP (mmHg) 79 ± 10 81 ± 8 73 ± 8* 72 ± 8* 72 ± 5*
LV EDP (mmHg) 13 ± 2 12 ± 2 11 ± 3* 10 ± 2* 9 ± 2*
EDV (ml) 69 ± 6 67 ± 6 67 ± 5 65 ± 5* 62 ± 4*
ESV (ml) 50 ± 5 47 ± 4* 45 ± 3* 42 ± 2* 40 ± 3*
EF (%) 28 ± 2.6 31 ± 4* 32 ± 3* 35 ± 6* 36 ± 4*
*=p<0.05 vs. Baseline
